PMA supplement
P130013 S077: WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY
FDA PMA supplement · Real-Time Process · Boston Scientific Corp
Key facts
| Original PMA | P130013 |
|---|---|
| Supplement number | S077 |
| Supplement type | Real-Time Process |
| Reason for the supplement | Change Design/Components/Specifications/Material |
| Trade name | WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY |
| Generic name | System, appendage closure, left atrial |
| Applicant | Boston Scientific Corp |
| Product code | NGV |
| Received date | Jun 6, 2025 |
| Decision date | Sep 4, 2025 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: